Jim Pratt
About Jim Pratt
Jim Pratt is the Associate Director of Statistics at Bristol-Myers Squibb in New Brunswick, New Jersey. He has extensive experience in biostatistics and data management, having previously held positions at Amylin Pharmaceuticals, ClinOps, Sonus Pharmaceuticals, Otsuka America, Procter & Gamble, and ManTech Environmental Technology, Inc.
Current Position at Bristol-Myers Squibb
Jim Pratt currently holds the title of Associate Director, Statistics at Bristol-Myers Squibb, based in New Brunswick, New Jersey. In this role, Jim utilizes his extensive background in biostatistics and statistical analysis, contributing to the company's efforts in clinical trial design and data interpretation.
Previous Roles in Biostatistics
Jim Pratt has a rich history in the field of biostatistics, having served as Associate Director, Biostatistics at Amylin Pharmaceuticals in San Diego, CA from 2010 to 2013. Prior to this role, he worked as Director, Biostatistics at ClinOps (formerly PDD and ClinPro) from 2008 to 2010 and as Director, Biostatistics and Data Management at Sonus Pharmaceuticals from 1999 to 2008. His early career included positions as Senior Biostatistician at Otsuka America, Biostatistician at Procter & Gamble, and Statistician at ManTech Environmental Technology, Inc.
Educational Background in Statistics
Jim Pratt earned a PhD in Statistics from Oregon State University, where he studied from 1988 to 1995. He also holds an MS in Statistics from the same institution, achieved after a one-year program from 1987 to 1988. His educational journey began with a BS in Mathematical Sciences, which he completed at Oregon State University from 1983 to 1987.
Specializations and Proficiencies
Jim Pratt specializes in Linear Models, Generalized Linear Models, Mixed Effects Models, Experimental Design, and Analyses. His technical skills include proficiency in the use of SAS and S-Plus for statistical analysis. These specializations enable him to effectively analyze and interpret complex data, contributing to the development of therapeutic products across various phases of clinical trials.
Contributions to Clinical Trials and Regulatory Submissions
Throughout his career, Jim Pratt has made significant contributions to the field of biostatistics. He has successfully presented and defended clinical trial design and analysis plans to the FDA for Phase 3 trials and NDA submission plans. His involvement in the development of clinical and regulatory submission strategies spans therapeutic areas such as oncology, antiseptic products, and vasomotor symptoms. Jim has also collaborated extensively with multidisciplinary teams including clinical, regulatory, manufacturing, analytical, ADME, and pharmacokinetics scientists.